BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson’s Disease to AbbVie After Receiving Clearance

BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson’s Disease to AbbVie After Receiving Clearance
STOCKHOLM, Dec. 14, 2018 /PRNewswire/ -- BioArctic AB (publ) (nasdaq stockholm:BIOA B) announced today that BioArctic and its partner AbbVie ABBV, -1.00% have received U.S. Federal Trade Commission (F ... read more
Source: Bing NewsPublished on 2018-12-13